Modotuximab
Modotuximab (INN; formerly zatuximab) is a chimeric monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to HER1.[1]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric |
Target | HER1 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG |
References
- World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.